Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy : A randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
Querol, Luis (Institut de Recerca Sant Pau)
De Sèze, J. (University Hospital of Strasbourg)
Dysgaard, T. (University of Copenhagen)
Levine, T. (Bob Bové Neuroscience Institute)
Rao, T.H. (The Neurological Institute. PA)
Rivner, M. (Augusta University)
Hartung, H.P. (Palacký University)
Kiessling, P. (UCB Pharma)
Shimizu, S. (UCB Pharma)
Marmol, D. (UCB Pharma)
Bozorg, A. (UCB Pharma)
Colson, A.O. (UCB Pharma)
Massow, U. (UCB Pharma)
Eftimov, F. (Amsterdam University Medical Center (UMC))
Universitat Autònoma de Barcelona

Fecha:	2024
Resumen:	Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor rozanolixizumab for CIDP management. Methods CIDP01 (NCT03861481) was a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a study. Adults with definite or probable CIDP receiving subcutaneous or intravenous immunoglobulin maintenance therapy were randomised 1:1 to 12 once-weekly subcutaneous infusions of rozanolixizumab 10 mg/kg or placebo, stratified according to previous immunoglobulin administration route. Investigators administering treatment and assessing efficacy, and patients, were blinded. The primary outcome was a change from baseline (CFB) to day 85 in inflammatory Rasch-built Overall Disability Scale (iRODS) score. Eligible patients who completed CIDP01 entered the open-label extension CIDP04 (NCT04051944). Results In CIDP01, between 26 March 2019 and 31 March 2021, 34 patients were randomised to rozanolixizumab or placebo (17 (50%) each). No significant difference in CFB to day 85 in iRODS centile score was observed between rozanolixizumab (least squares mean 2. 0 (SE 3. 2)) and placebo (3. 4 (2. 6); difference -1. 5 (90% CI -7. 5 to 4. 5)). Overall, 14 (82%) patients receiving rozanolixizumab and 13 (76%) receiving placebo experienced a treatment-emergent adverse event during the treatment period. Across CIDP01 and CIDP04, rozanolixizumab was well tolerated over up to 614 days; no clinically meaningful efficacy results were seen. No deaths occurred. Conclusions Rozanolixizumab did not show efficacy in patients with CIDP in this study, although this could be due to a relatively high placebo stability rate. Rozanolixizumab was well tolerated over medium-to-long-term weekly use, with an acceptable safety profile.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	FC RECEPTOR ; MOVEMENT DISORDERS ; MYASTHENIA ; NEUROMUSCULAR ; RANDOMISED TRIALS
Publicado en:	Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 95 Núm. 9 (16 2024) , p. 845-854, ISSN 1468-330X

DOI: 10.1136/jnnp-2023-333112
PMID: 38729747

10 p, 435.7 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados